
Gene Editing Gets Ready for the Spotlight
Pharma has invested billions in cell and gene therapies. Gene editing is making a case for more of this funding, but companies need to understand what they’re investing in and why.
Pharma has invested billions in cell and gene therapies. Gene editing is making a case for more of this funding, but companies need to understand what they’re investing in and why.
To become leaders in the field, biopharma companies must understand unmet needs and evolving standards of care and make greater use of real-world evidence.
Companies can take four steps to address the inequitable health outcomes that marginalized and underserved communities experience in the US.
For their investments to pay off, biopharma companies need the right organizational setup and ways of working.
A confluence of factors means the time-tested approaches to cost control won’t work. Insurers need to rethink how they achieve more with less while maintaining a strong customer focus and employee value proposition.
A new regulation makes detailed pricing data widely available for the first time. Providers and insurers need to prepare now for a changed competitive playing field.
An employee value proposition can help companies keep current employees and attract new ones.
As competition grows, plans need to win their members’ trust—and their renewal—every year. Here’s how to do it.
A global leader in prostheses, Ottobock set out to also become the ESG leader in its field. The key: measuring the socioeconomic benefit of its products.
When patients move through hospital units—and eventually are discharged—their vital information doesn’t follow. But smarter solutions can track patient data across settings.
A sea change is underway in how companies win regulatory approval for new health care products—particularly in the use of digital technology—and which markets they prioritize.
A next-generation commercial model is needed fast. Those who adopt it quickly will be rewarded handsomely.
BCG Executive Perspectives offer insights on global topics that matter most to leaders in the public and private sectors. Our latest edition explores the evolving landscape of business and leisure travel, examining how companies within and beyond the industry can adapt to new trends.
What has worked, what can be improved, and what needs to be reimagined so that we are better prepared for the next pandemic and better able to improve health in the world’s poorest nations?
BCG Managing Director & Partner Johanna Benesty looks at barriers to "equitable access"—making sure COVID-19 therapeutics are available to all—while sharing a creative approach to vaccine research and development.